Seattle Genetics gets a PhIII win for Adcetris, but shares slide as frets linger
Seattle Genetics $SGEN has had a rough Q2 as its lead experimental therapy was put back on hold, forcing investigators to scrap Phase III shortly after the biotech had to drop a deal with Immunomedics. But it’s winding up the quarter with a major win in its favor, posting a hit in its closely-watched Echelon-1 study for frontline Hodgkin lymphoma.
The big biotech says that its flagship therapy, Adcetris, combined with a trio of standard drugs beat a 4-drug mainstay cocktail therapy in frontline Hodgkin disease for modified progression-free survival over a lengthy two-year stretch. The Adcetris package excluded bleomycin, which has been linked to a higher rate of lung toxicity and was used in the 4-drug combo control.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.